Seminars in Hematology
Volume 46, Supplement 3 , Pages S27-S33, April 2009

New Directions in the Treatment of Imatinib Failure and/or Resistance

  • Francis J. Giles

      Affiliations

    • Corresponding Author InformationAddress correspondence to Francis J. Giles, MD, FRCPI, FRCPath, CTRC at the University of Texas Health Science Center at San Antonio, 7979 Wurzbach Rd, San Antonio, TX 78229

Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio, San Antonio, TX

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Editorial support was provided by Jeni Fagan (Health Interactions) on behalf of Novartis Oncology.

 STATEMENT OF CONFLICT OF INTEREST: Dr Giles received research support from Novartis Pharmaceuticals Corp.

PII: S0037-1963(09)00022-5

doi:10.1053/j.seminhematol.2009.01.011

Seminars in Hematology
Volume 46, Supplement 3 , Pages S27-S33, April 2009

Article Tools

* Image Usage & Resolution